LV15670A - Jauni adenozilmerkaptāna atvasinājumi kā vīrusu m-RNS kapinga metiltransferāžu inhibitori - Google Patents

Jauni adenozilmerkaptāna atvasinājumi kā vīrusu m-RNS kapinga metiltransferāžu inhibitori

Info

Publication number
LV15670A
LV15670A LVP-21-16A LVP2021000016A LV15670A LV 15670 A LV15670 A LV 15670A LV P2021000016 A LVP2021000016 A LV P2021000016A LV 15670 A LV15670 A LV 15670A
Authority
LV
Latvia
Prior art keywords
adenosylmercaptane
mrna cap
derivatives
viral mrna
novel
Prior art date
Application number
LVP-21-16A
Other languages
English (en)
Inventor
Olga BOBIĻEVA
Raitis BOBROVS
Iveta KAŅEPE
Gints KALNIŅŠ
Mihails ŠIŠOVS
Anna LĪNA BULA
Aigars Jirgensons
Kaspars TĀRS
Kristaps JAUDZEMS
Original Assignee
Latvijas Organiskās Sintēzes Institūts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvijas Organiskās Sintēzes Institūts filed Critical Latvijas Organiskās Sintēzes Institūts
Priority to LVP-21-16A priority Critical patent/LV15670B/lv
Priority to PCT/IB2021/061623 priority patent/WO2022189846A1/en
Publication of LV15670A publication Critical patent/LV15670A/lv
Publication of LV15670B publication Critical patent/LV15670B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Abstract

Izgudrojums attiecas uz medicīnu, galvenokārt uz vīrusu infekcijas ārstēšanu, konkrētāk uz vīrusu m-RNS kapinga metiltransferāzes inhibitoriem. Piedāvāti jauni adenozilmerkaptāna atvasinājumi, to farmaceitiskās kompozīcijas un to izmantošana par m-RNS kapinga metiltransferāzes inhibitoriem.
LVP-21-16A 2021-03-10 2021-03-10 Jauni adenozilmerkaptāna atvasinājumi kā vīrusu m-RNS kapinga metiltransferāžu inhibitori LV15670B (lv)

Priority Applications (2)

Application Number Priority Date Filing Date Title
LVP-21-16A LV15670B (lv) 2021-03-10 2021-03-10 Jauni adenozilmerkaptāna atvasinājumi kā vīrusu m-RNS kapinga metiltransferāžu inhibitori
PCT/IB2021/061623 WO2022189846A1 (en) 2021-03-10 2021-12-13 NOVEL ADENOSYLMERCAPTANE DERIVATIVES AS VIRAL mRNA CAP METHYLTRANSFERASE INHIBITORS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-21-16A LV15670B (lv) 2021-03-10 2021-03-10 Jauni adenozilmerkaptāna atvasinājumi kā vīrusu m-RNS kapinga metiltransferāžu inhibitori

Publications (2)

Publication Number Publication Date
LV15670A true LV15670A (lv) 2022-09-20
LV15670B LV15670B (lv) 2023-11-20

Family

ID=79093076

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-21-16A LV15670B (lv) 2021-03-10 2021-03-10 Jauni adenozilmerkaptāna atvasinājumi kā vīrusu m-RNS kapinga metiltransferāžu inhibitori

Country Status (2)

Country Link
LV (1) LV15670B (lv)
WO (1) WO2022189846A1 (lv)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074083A1 (en) * 2002-03-04 2003-09-12 Pfizer Inc. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
WO2011075665A2 (en) * 2009-12-18 2011-06-23 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074083A1 (en) * 2002-03-04 2003-09-12 Pfizer Inc. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
WO2011075665A2 (en) * 2009-12-18 2011-06-23 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOBILEVA OLGA ET AL: "Potent SARS-CoV-2 mRNA Cap Methyltransferase Inhibitors by Bioisosteric Replacement of Methionine in SAM Cosubstrate", ACS MEDICINAL CHEMISTRY LETTERS, vol. 12, no. 7, 8 July 2021 (2021-07-08), US, pages 1102 - 1107, XP055855723, ISSN: 1948-5875, DOI: 10.1021/acsmedchemlett.1c00140 *
MAHALAPBUTR PANUPONG ET AL: "Structural insight into the recognition of S-adenosyl-L-homocysteine and sinefungin in SARS-CoV-2 Nsp16/Nsp10 RNA cap 2'-O-Methyltransferase", COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, vol. 18, 1 October 2020 (2020-10-01), Sweden, pages 2757 - 2765, XP055855730, ISSN: 2001-0370, DOI: 10.1016/j.csbj.2020.09.032 *
PUGH RICHARD ET AL: "Inhibition of Newcastle Disease Virion Messenger RNA (guanine-7-)-Methyltransferase by Analogues of S-Adenosylhomocysteine", BIOCHEMISTRY, vol. 16, no. 17, 1 January 1977 (1977-01-01), pages 3928 - 3932, XP055855728 *

Also Published As

Publication number Publication date
WO2022189846A1 (en) 2022-09-15
LV15670B (lv) 2023-11-20

Similar Documents

Publication Publication Date Title
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MY197635A (en) Benzooxazole derivatives as immunomodulators
MX2022002938A (es) Compuestos inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) cooperativos para metiltioadenosina (mta).
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
MX2018005019A (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
MX2019013735A (es) Antimitoscinas: inhibidores especificos de la biogenesis mitocondrial para erradicar celulas madre cancerosas.
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
MX2022014007A (es) Compuestos como inhibidores de bcl-2.
MX2021001376A (es) Carboxamidas como inhibidores de proteasa específicos de ubiquitina.
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
MX2017015029A (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak.
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
MX2020005880A (es) Derivados de pirrol como inhibidores de acc.
MX2018009870A (es) Inhibidores de taf1 para la terapia del cancer.
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
GEP20247585B (en) Furoindazole derivatives
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2021013602A (es) Inhibidores de jak.
PH12015502589A1 (en) 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives
MX2022004419A (es) Derivados de [1,4]oxazepino[2,3c]quinolinona como inhibidores de bcl6.
EP4282414A3 (en) Modified release tablet formulations containing phosphodiesterase inhibitors
PH12019501999A1 (en) Pyrazole derivatives as bromodomain inhibitors